Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial

Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial

Objective: Conversion therapy (surgical resection after chemotherapy) is a promising option for unresectable gastric cancer (GC) patients. Addition of anti-angiogenesis drug improves response to chemotherapy. Hence, this study explored the feasibility and efficacy of preoperative paclitaxel (PTX)/S1...

Full description

Bibliographic Details
Main Authors: Zhiyuan Xu, Can Hu, Jianfa Yu, Yian Du, Ping Hu, Guofa Yu, Conggang Hu, Yu Zhang, Wei Mao, Shanqi Chen, Xiangdong Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Pharmacology
Subjects:
gastric cancer
conversion surgery
apatinib
safety
unresectable abdominal neoplasms
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.642511/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.642511/full

Similar Items